Short description
MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need
Description
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Foster City, California, United States, North America
Founded on
January 1, 2007
Exited on
August 4, 2022
Went public on
August 4, 2022
Stock symbol
688373
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Nopepepe, Blurry Noaccess, Uh Ohhhh, Noaccess, Uh Ohhhh, Absolutely Noaccess, Nopepepe, Absolutely Noaccess, Cannot Access, Noaccess, No Way, Blurry Noaccess, Noaccessforu, Noaccess, Noaccess, Nopepepe, Noaccess, Noaccess
Sign in for full access
Founders
Mike F. Gordeev, Zhengyu Yuan